Omeros (NASDAQ:OMER) Lowered to “Sell” Rating by StockNews.com

StockNews.com lowered shares of Omeros (NASDAQ:OMER) from a hold rating to a sell rating in a report released on Tuesday.

Omeros Stock Down 0.7 %

NASDAQ OMER opened at $4.26 on Tuesday. The company has a 50 day moving average price of $4.01 and a 200 day moving average price of $4.04. Omeros has a 52 week low of $1.17 and a 52 week high of $5.68. The firm has a market cap of $246.85 million, a PE ratio of -1.81 and a beta of 1.47.

Institutional Trading of Omeros

Hedge funds and other institutional investors have recently made changes to their positions in the business. SPC Financial Inc. acquired a new position in shares of Omeros in the 3rd quarter valued at about $77,000. SG Americas Securities LLC purchased a new position in Omeros in the third quarter valued at $80,000. Oppenheimer & Co. Inc. purchased a new stake in shares of Omeros during the 1st quarter worth about $85,000. Comerica Bank grew its position in shares of Omeros by 20.0% during the 1st quarter. Comerica Bank now owns 30,000 shares of the biopharmaceutical company’s stock valued at $104,000 after acquiring an additional 5,000 shares during the period. Finally, BNP Paribas Financial Markets raised its holdings in Omeros by 75.5% in the 1st quarter. BNP Paribas Financial Markets now owns 30,102 shares of the biopharmaceutical company’s stock worth $104,000 after purchasing an additional 12,951 shares during the period. Institutional investors and hedge funds own 48.79% of the company’s stock.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.